Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Update on Male Hormonal Contraception: Is the Vasectomy in Jeopardy?

Abstract

Traditionally, male contraception has consisted of either barrier methods, such as condoms, or vasectomy. However, in recent years, we have made great strides in the basic science and clinical medicine to better understand the feedback mechanisms and physiology of the male reproductive system. These advances have enabled the development of several nonsurgical, hormonal, reversible, well-tolerated alternatives for male contraception. Men are more likely now than ever to participate in the choice of contraceptive techniques. This review will discuss the current status and recent developments in nonsurgical hormonal male contraception, a field that has been historically limited by social, financial and physiological challenges.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Smith JC, Cranston D, O'Brien T, Guillebaud J, Hindmarsh J, Turner AG . Fatherhood without apparent spermatozoa after vasectomy. Lancet 1994; 344: 30.

    CAS  PubMed  Google Scholar 

  2. Heinemann K, Saad F, Wiesemes M, White S, Heinemann L . Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod 2005; 20: 549–556.

    PubMed  Google Scholar 

  3. Glasier AF, Anakwe R, Everington D, Martin CW, van der Spuy Z, Cheng L et al. Would women trust their partners to use a male pill? Hum Reprod 2000; 15: 646–649.

    CAS  PubMed  Google Scholar 

  4. Finer LB, Henshaw SK . Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006; 38: 90–96.

    PubMed  Google Scholar 

  5. Hayes FJ, DeCruz S, Seminara SB, Boepple PA, Crowley Jr WF . Differential regulation of gonadotropin secretion by testosterone in the human male: absence of a negative feedback effect of testosterone on follicle-stimulating hormone. J Clin Endocrinol Metab 2001; 86: 53–58.

    CAS  PubMed  Google Scholar 

  6. Schnorr JA, Bray MJ, Veldhuis JD . Aromatization mediates testosterone's short term feedback restraint of 24-hour endogenously driven and acute endogenous gonadotropin-releasing hormone stimulated luteinizing hormone and follicle stimulating hormone secretion in young men. J Clin Endocrinol Metab 2001; 86: 2600–2606.

    CAS  PubMed  Google Scholar 

  7. Novaira HJ, Ng Y, Wolfe A, Radovick S . Kisspeptin increases GnRH mRNA expression and secretion in GnRH secreting neuronal cell lines. Mol Cell Endocrinol 2009; 311: 126–134.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Page ST, Amory JK, Bremner WJ . Advances in male contraception. Endocr Rev 2008; 29: 465–493.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Seminara SB, Dipietro MJ, Ramaswamy S, Crowley Jr WF, Plant TM . Continuous human metastin 45-54 infusion desensitizes G protein-coupled receptor 54-induced gonadotropin-releasing hormone release monitored indirectly in the juvenile male Rhesus monkey (Macaca mulatta): a finding with therapeutic implications. Endocrinology 2006; 147: 2122–2126.

    CAS  PubMed  Google Scholar 

  10. Soriano-Guillen L, Mitchell V, Carel JC, Barbet P, Roger M, Lahlou N . Activating mutations in the luteinizing hormone receptor gene: a human model of non-follicle-stimulating hormone-dependent inhibin production and germ cell maturation. J Clin Endocrinol Metab 2006; 91: 3041–3047.

    CAS  PubMed  Google Scholar 

  11. Matthiesson KL, Robertson DM, Burger HG, McLachlan RI . Response of serum inhibin B and pro-alphaC levels to gonadotrophic stimulation in normal men before and after steroidal contraceptive treatment. Hum Reprod 2003; 18: 734–743.

    CAS  PubMed  Google Scholar 

  12. McLachlan RI, Robertson DM, Pruysers E, Ugoni A, Matsumoto AM, Anawalt BD et al. Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment. J Clin Endocrinol Metab 2004; 89: 142–149.

    CAS  PubMed  Google Scholar 

  13. Shah C, Modi D, Sachdeva G, Gadkar S, Puri C . Coexistence of intracellular and membrane-bound progesterone receptors in human testis. J Clin Endocrinol Metab 2005; 90: 474–483.

    CAS  PubMed  Google Scholar 

  14. Coviello AD, Bremner WJ, Matsumoto AM, Herbst KL, Amory JK, Anawalt BD et al. Intratesticular testosterone concentrations comparable with serum levels are not sufficient to maintain normal sperm production in men receiving a hormonal contraceptive regimen. J Androl 2004; 25: 931–938.

    CAS  PubMed  Google Scholar 

  15. Coviello AD, Matsumoto AM, Bremner WJ, Herbst KL, Amory JK, Anawalt BD et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab 2005; 90: 2595–2602.

    CAS  PubMed  Google Scholar 

  16. Heller CG, Rowley MJ, Heller GV . Clomiphene citrate: a correlation of its effect on sperm concentration and morphology, total gonadotropins, ICSH, estrogen and testosterone excretion, and testicular cytology in normal men. J Clin Endocrinol Metab 1969; 29: 638–649.

    CAS  PubMed  Google Scholar 

  17. Huhtaniemi I, Nikula H, Rannikko S . Pituitary–testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. I. Circulating hormone levels. J Androl 1987; 8: 355–362.

    CAS  PubMed  Google Scholar 

  18. McLachlan RI, O'Donnell L, Stanton PG, Balourdos G, Frydenberg M, de Kretser DM et al. Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men. J Clin Endocrinol Metab 2002; 87: 546–556.

    CAS  PubMed  Google Scholar 

  19. Zhang FP, Pakarainen T, Poutanen M, Toppari J, Huhtaniemi I . The low gonadotropin-independent constitutive production of testicular testosterone is sufficient to maintain spermatogenesis. Proc Natl Acad Sci USA 2003; 100: 13692–13697.

    CAS  PubMed  Google Scholar 

  20. Zhang FP, Pakarainen T, Zhu F, Poutanen M, Huhtaniemi I . Molecular characterization of postnatal development of testicular steroidogenesis in luteinizing hormone receptor knockout mice. Endocrinology 2004; 145: 1453–1463.

    CAS  PubMed  Google Scholar 

  21. Meriggiola MC, Costantino A, Bremner WJ, Morselli-Labate AM . Higher testosterone dose impairs sperm suppression induced by a combined androgen–progestin regimen. J Androl 2002; 23: 684–690.

    CAS  PubMed  Google Scholar 

  22. Amory JK, Wang C, Swerdloff RS, Anawalt BD, Matsumoto AM, Bremner WJ et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab 2007; 92: 1659–1665.

    CAS  PubMed  Google Scholar 

  23. Tsai MY, Yeh SD, Wang RS, Yeh S, Zhang C, Lin HY et al. Differential effects of spermatogenesis and fertility in mice lacking androgen receptor in individual testis cells. Proc Natl Acad Sci USA 2006; 103: 18975–18980.

    CAS  PubMed  Google Scholar 

  24. Chang C, Chen YT, Yeh SD, Xu Q, Wang RS, Guillou F et al. Infertility with defective spermatogenesis and hypotestosteronemia in male mice lacking the androgen receptor in Sertoli cells. Proc Natl Acad Sci USA 2004; 101: 6876–6881.

    CAS  PubMed  Google Scholar 

  25. De Gendt K, Swinnen JV, Saunders PT, Schoonjans L, Dewerchin M, Devos A et al. A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci USA 2004; 101: 1327–1332.

    CAS  PubMed  Google Scholar 

  26. Holdcraft RW, Braun RE . Androgen receptor function is required in Sertoli cells for the terminal differentiation of haploid spermatids. Development 2004; 131: 459–467.

    CAS  PubMed  Google Scholar 

  27. Zhang C, Yeh S, Chen YT, Wu CC, Chuang KH, Lin HY et al. Oligozoospermia with normal fertility in male mice lacking the androgen receptor in testis peritubular myoid cells. Proc Natl Acad Sci USA 2006; 103: 17718–17723.

    CAS  PubMed  Google Scholar 

  28. O'Donnell L, Pratis K, Stanton PG, Robertson DM, McLachlan RI . Testosterone-dependent restoration of spermatogenesis in adult rats is impaired by a 5alpha-reductase inhibitor. J Androl 1999; 20: 109–117.

    CAS  PubMed  Google Scholar 

  29. Steinberger E . Hormonal control of mammalian spermatogenesis. Physiol Rev 1971; 51: 1–22.

    CAS  PubMed  Google Scholar 

  30. Turner TT, Howards SS, Gleavy JL . On the maintenance of male fertility in the absence of native testosterone secretion: site-directed hormonal therapy in the rat. Fertil Steril 1990; 54: 149–156.

    CAS  PubMed  Google Scholar 

  31. Simoni M, Weinbauer GF, Gromoll J, Nieschlag E . Role of FSH in male gonadal function. Ann Endocrinol (Paris) 1999; 60: 102–106.

    CAS  Google Scholar 

  32. Ruwanpura SM, McLachlan RI, Matthiesson KL, Meachem SJ . Gonadotrophins regulate germ cell survival, not proliferation, in normal adult men. Hum Reprod 2008; 23: 403–411.

    CAS  PubMed  Google Scholar 

  33. Heckel NJ . Production of oligospermia in a man by the use of testosterone propionate. Proc Soc Exp Biol Med 1939; 40: 658–659.

    Google Scholar 

  34. McCullagh EP, McGurl FJ . Further observations on the clinical use of testosterone propionate. J Urol 1939; 42: 1265–1267.

    Google Scholar 

  35. Nieschlag E . 10th summit meeting consensus: recommendations for regulatory approval for hormonal male contraception. Contraception 2007; 75: 166–167.

    PubMed  Google Scholar 

  36. Wenk M, Nieschlag E . Male contraception: a realistic option? Eur J Contracept Reprod Health Care 2006; 11: 69–80.

    PubMed  Google Scholar 

  37. Hoesl CE, Saad F, Poppel M, Altwein JE . Reversible, non barrier male contraception: status and prospects. Eur Urol 2005; 48: 712–713.

    CAS  PubMed  Google Scholar 

  38. Anderson RA, Baird DT . Male contraception. Endocr Rev 2002; 23: 735–762.

    CAS  PubMed  Google Scholar 

  39. Pasqualotto FF, Lucon AM, Pasqualotto EB, Arap S . Trends in male contraception. Rev Hosp Clin Fac Med Sao Paulo 2003; 58: 275–283.

    PubMed  Google Scholar 

  40. Herdiman J, Nakash A, Beedham T . Male contraception: past, present and future. J Obstet Gynaecol 2006; 26: 721–727.

    CAS  PubMed  Google Scholar 

  41. Handelsman DJ . Editorial. Hormonal male contraception—lessons from the East when the Western market fails. J Clin Endocrinol Metab 2003; 88: 559–561.

    PubMed  Google Scholar 

  42. Matthiesson KL, McLachlan RI . Male hormonal contraception: concept proven, product in sight? Hum Reprod Update 2006; 12: 463–482.

    CAS  PubMed  Google Scholar 

  43. Naz RK, Rowan S . Update on male contraception. Curr Opin Obstet Gynecol 2009; 21: 265–269. Review.

    PubMed  Google Scholar 

  44. Reddy PR, Rao JM . Reversible antifertility action of testosterone propionate in human males. Contraception 1972; 5: 295–301.

    CAS  PubMed  Google Scholar 

  45. WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990; 336: 955–959.

    Google Scholar 

  46. Lookingbill DP, Demers LM, Wang C, Leung A, Rittmaster RS, Santen RJ . Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J Clin Endocrinol Metab 1991; 72: 1242–1248.

    CAS  PubMed  Google Scholar 

  47. Kornmann B, Nieschlag E, Zitzmann M, Gromoll J, Simoni M, von Eckardstein S . Body fat content and testosterone pharmacokinetics determine gonadotropin suppression after intramuscular injections of testosterone preparations in normal men. J Androl 2009; 30: 602–613.

    CAS  PubMed  Google Scholar 

  48. WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 1996; 65: 821–882.

    Google Scholar 

  49. Gu YQ, Wang XH, Xu D, Peng L, Cheng LF, Huang MK et al. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab 2003; 88: 562–568.

    CAS  PubMed  Google Scholar 

  50. Gu Y, Liang X, Wu W, Liu M, Song S, Cheng L et al. Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab 2009; 94: 1910–1915.

    CAS  PubMed  Google Scholar 

  51. Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E . Potential of testosterone buciclate for male contraception: endocrine differences between responders and non-responders. J Clin Endocrinol Metab 1995; 80: 2394–2403.

    CAS  PubMed  Google Scholar 

  52. Eckardstein S, Noe G, Brache V, Nieschlag E, Croxatto H, Alvarez F et al. A clinical trial of 7 alpha methyl-19-nortestosterone implants for possible use as a long-acting contraceptive in men. J Clin Endocrinol Metab 2003; 88: 5232–5239.

    Google Scholar 

  53. Suvisaari J, Sundaram K, Noé G, Kumar N, Aguillaume C, Tsong YY et al. Pharmacokinetics and pharmacodynamics of 7alpha-methyl-19-nortestosterone after intramuscular administration in healthy men. Hum Reprod 2997; 12: 967–973.

    Google Scholar 

  54. Attardi BJ, Hild SA, Reel JR . Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. Endocrinology 2006; 147: 3016–3026.

    CAS  PubMed  Google Scholar 

  55. Amory JK, Page ST, Anawalt BD, Matsumoto AM, Bremner WJ . Elevated serum INSL3 is associated with failure to completely suppress spermatogenesis in men receiving male hormonal contraception. J Androl 2007; 28 (Suppl 2): 46.

    Google Scholar 

  56. El-Hefnawy T, Huhtaniemi I . Progesterone can participate in down-regulation of the luteinizing hormone receptor gene expression and function in cultured murine Leydig cells. Mol Cell Endocrinol 1998; 137: 127–138.

    CAS  PubMed  Google Scholar 

  57. El-Hefnawy T, Manna PR, Luconi M, Baldi E, Slotte JP, Huhtaniemi I . Progesterone action in a murine Leydig tumor cell line (mLTC-1), possibly through a nonclassical receptor type. Endocrinology 2000; 141: 247–255.

    CAS  PubMed  Google Scholar 

  58. Anderson RA, van def Spuy ZM, Dada OA, Tregoning SK, Zinn PM, Adeniji OA et al. Investigation of hormonal male contraception in African men: suppression of spermatogenesis by oral desogestrel with depot testosterone. Hum Reprod 2002; 17: 2869–2877.

    CAS  PubMed  Google Scholar 

  59. Grimes DA, Gallo MF, Grigorieva V, Nanda K, Schulz KF . Steroid hormones for contraception in men: systematic review of randomized controlled trials. Contraception 2005; 71: 89–94.

    CAS  PubMed  Google Scholar 

  60. Meriggiola MC, Farley TM, Mbizvo MT . A review of androgen–progestin regimens for male contraception. J Androl 2003; 24: 466–483.

    CAS  PubMed  Google Scholar 

  61. WHO Task Force on Methods for the Regulation of Male Fertility. Comparison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in Indonesian men. Fertil Steril 1993; 60: 1062–1068.

    Google Scholar 

  62. Turner L, Conway AJ, Jimenez M, Liu PY, Forbes E, McLachlan RI et al. Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab 2003; 88: 4659–4667.

    CAS  PubMed  Google Scholar 

  63. Amory JK, Page ST, Anawalt BD, Matsumoto AM, Bremner WJ . Acceptability of a combination testosterone gel and depomedroxyprogesterone acetate male contraceptive regimen. Contraception 2007; 75: 218–223.

    CAS  PubMed  Google Scholar 

  64. Page ST, Amory JK, Anawalt BD, Irwig MS, Brockenbrough AT, Matsumoto AM et al. Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endo Metab 2006; 91: 4374–4380.

    CAS  Google Scholar 

  65. Kawamura K, Kumagai J, Sudo S, Chun SY, Pisarska M, Morita H et al. Paracrine regulation of mammalian oocyte maturation and germ cell survival. Proc Natl Acad Sci USA 2004; 101: 7323–7328.

    CAS  PubMed  Google Scholar 

  66. Petry R, Mauss J, Rausch-Stroomann JG, Vermeulen A . Reversible inhibition of spermatogenesis in men. Horm Metab Res 1972; 4: 386–388.

    CAS  PubMed  Google Scholar 

  67. Fredricsson B, Carlstrom K . Effects of low doses of cyproterone acetate on sperm morphology and some other parameters of reproduction in normal men. Andrologia 1981; 13: 369–375.

    CAS  PubMed  Google Scholar 

  68. Roy S, Chatterjee S, Prasad MR, Poddar AK, Pandey DC . Effects of cyproterone acetate on reproductive functions in normal human males. Contraception 1976; 14: 403–420.

    CAS  PubMed  Google Scholar 

  69. Meriggiola MC, Bremner WJ, Paulsen CA, Valdiserri A, Incorvaia L, Motta R et al. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J Clin Endocrinol Metab 1996; 81: 3018–3023.

    CAS  PubMed  Google Scholar 

  70. Meriggiola MC, Bremner WJ, Costantino A, Pavani A, Capelli M, Flamigni C . An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. Fertil Steril 1997; 68: 844–850.

    CAS  PubMed  Google Scholar 

  71. Meriggiola MC, Bremner WJ, Costantino A, Di Cintio G, Flamigni C . Low dose of cyproterone acetate and testosterone enanthate for contraception in men. Hum Reprod 1998; 13: 1225–1229.

    CAS  PubMed  Google Scholar 

  72. Meriggiola MC, Costantino A, Bremner WJ, Morselli-Labate AM . Higher testosterone dose impairs sperm suppression induced by a combined androgen–progestin regimen. J Androl 2002; 23: 684–690.

    CAS  PubMed  Google Scholar 

  73. Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM . A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl 1999; 20: 407–414.

    CAS  PubMed  Google Scholar 

  74. Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Brenmner WJ, Matsumoto AM . Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab 1996; 81: 757–762.

    CAS  PubMed  Google Scholar 

  75. Gui YL, He CH, Amory JK, Bremner WJ, Zheng EX, Yang J et al. Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in Chinese men. J Androl 2004; 25: 720–727.

    CAS  PubMed  Google Scholar 

  76. Kinniburgh D, Zhu H, Cheng L, Kicman AT, Baird DT, Anderson RA . Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. Hum Reprod 2002; 17: 1490–1501.

    CAS  PubMed  Google Scholar 

  77. Brady BM, Walton M, Hollow N, Kicman AT, Baird DT, Anderson RA . Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception. Hum Reprod 2004; 19: 2658–2667.

    CAS  PubMed  Google Scholar 

  78. Brady BM, Amory JK, Perheentupa A, Zitzmann M, Hay CJ, Apter D et al. A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive. Hum Reprod 2006; 21: 285–294.

    CAS  PubMed  Google Scholar 

  79. Walton MJ, Kumar N, Baird DT, Ludlow H, Anderson RA . 7alpha-methyl-19-nortestosterone (MENT) vs testosterone in combination with etonogestrel implants for spermatogenic suppression in healthy men. J Androl 2007; 28: 679–688.

    CAS  PubMed  Google Scholar 

  80. Meriggiola MC, Bremner WJ, Costantino A, Bertaccini A, Morselli-Labate AM, Huebler D et al. Twenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal men. J Clin Endocrinol Metab 2002; 87: 2107–2113.

    CAS  PubMed  Google Scholar 

  81. Misro MM, Chaki SP, Kaushik MC, Nandan D . Trials for development of once-a-month injectable, hormonal male contraceptive using dienogest plus testosterone undecanoate: dose standardization, efficacy and reversibility studies in rats. Contraception 2009; 79: 488–497.

    CAS  PubMed  Google Scholar 

  82. Guerin JF, Rollet J . Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens. Int J Androl 1988; 11: 187–199.

    CAS  PubMed  Google Scholar 

  83. Kamischke A, Heuermann T, Kruger K, von Eckardstein S, Schellschmidt I, Rübig A et al. An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable Norethisterone preparations. J Clin Endocrinol Metab 2002; 87: 530–539.

    CAS  PubMed  Google Scholar 

  84. Meriggiola MC, Costantino A, Saad F, D'Emidio L, Morselli Labate AM, Bertaccini A et al. Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis and prostate. J Clin Endocrinol Metab 2005; 90: 2005–2014.

    CAS  PubMed  Google Scholar 

  85. Mahabadi V, Amory JK, Swerdloff RS, Bremner WJ, Page ST, Sitruk-Ware R et al. Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men. J Clin Endocrinol Metab 2009; 94: 2313–2320.

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Huhtaniemi I, Nikula H, Ranniko S . Treatment of prostatic cancer with a gonadotropin releasing hormone agonist analog: acute and long term effects on endocrine functions of testis tissue. J Clin Endocrinol Metab 1985; 61: 698–704.

    CAS  PubMed  Google Scholar 

  87. Nieschlag E, Behre HM, Weinbauer GF . Hormonal male contraception: a real chance?. In: Nieschlag E, Habenicht UF (eds). Spermatogenesis–Fertilization–Contraception. Molecular, Cellular and Endocrine Events in Male Reproduction. Springer: Berlin, Heidelberg, New York, 1992 pp 477–501.

    Google Scholar 

  88. Pavlou SN, Brewer K, Farley MG, Lindner J, Bastias MC, Rogers BJ et al. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. J Clin Endocrinol Metab 1991; 73: 1360–1369.

    CAS  PubMed  Google Scholar 

  89. Tom L, Bhasin S, Salameh W, Steiner B, Peterson M, Sokol RZ et al. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. J Clin Endocrinol Metab 1992; 75: 476–483.

    CAS  PubMed  Google Scholar 

  90. Bastias MC, Kamijo H, Pavlou SN . Sperm motion parameters after suppression of spermatogenesis with a gonadotropin-releasing hormone antagonist plus testosterone supplementation. Fertil Steril 1993; 59: 1261–1265.

    CAS  PubMed  Google Scholar 

  91. Bagatell CJ, Matsumoto AM, Christensen RB, Rivier JE, Bremner WJ . Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J Clin Endocrinol Metab 1993; 77: 427–432.

    CAS  PubMed  Google Scholar 

  92. Bagatell CJ, Rivier JE, Bremner WJ . Dose effects of the gonadotropin-releasing hormone antagonist, Nal-Glu, combined with testosterone enanthate on gonadotropin levels in normal men. Fertil Steril 1995; 64: 139–145.

    CAS  PubMed  Google Scholar 

  93. Behre HM, Kliesch S, Lemcke B, von Eckardstein S, Nieschlag E . Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. Hum Reprod 2001; 16: 2570–2577.

    CAS  PubMed  Google Scholar 

  94. Murdoch WJ . Immunoregulation of mammalian fertility. Life Sci 1994; 55: 1871–1886.

    CAS  PubMed  Google Scholar 

  95. Moudgal NR, Jeyakumar M, Krishnamurthy HN, Sridhar S, Martin F . Development of male contraceptive vaccine—a perspective. Hum Reprod Update 1997; 3: 335–346.

    CAS  PubMed  Google Scholar 

  96. Talwar GP . Vaccines for control of fertility and hormone-dependent cancers. Immunol Cell Biol 1997; 75: 184–189.

    CAS  PubMed  Google Scholar 

  97. Chen J, Hwang DJ, Bohl CE, Miller DD, Dalton JT . A selective androgen receptor modulator (SARM) for hormonal male contraception. J Pharmacol Exp Ther 2004; 312: 546–553.

    PubMed  Google Scholar 

  98. Jones A, Chen J, Hwang DJ, Miller DD, Dalton JT . Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception. Endocrinology 2009; 150: 385–395.

    CAS  PubMed  Google Scholar 

  99. Klotz KL, Coppola MA, Labrecque M, Brugh III VM, Ramsey K, Kim KA et al. Clinical and consumer trial performance of a sensitive immunodiagnostic home test that qualitatively detects low concentrations of sperm following vasectomy. J Urol 2008; 180: 2569–2576.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S C Honig.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

This article has drawn upon material from Honig SC and Sandlow J. Male contraception and vasectomy. In: Lipshultz L, Howards SS, Niederberger CS (eds). Infertility in the Male, 4th edn. Cambridge University Press: Cambridge, UK, 2009, pp 474–492, reproduced with permission.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Manetti, G., Honig, S. Update on Male Hormonal Contraception: Is the Vasectomy in Jeopardy?. Int J Impot Res 22, 159–170 (2010). https://doi.org/10.1038/ijir.2010.2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2010.2

Keywords

This article is cited by

Search

Quick links